The shares of New York Mortgage Trust, Inc. (NASDAQ:NYMT) has been pegged with a rating of Underweight by Barclays in its latest research note that was published on February 28th, 2019. The research company has also assigned a $5 price target. Barclays wasn’t the only research firm that published a report of New York Mortgage Trust, Inc., with other equities research analysts also giving their opinion on the stock. Maxim Group advised investors in its research note published on February 21st, 2018, to Buy the NYMT stock while also putting a $6.25 price target. The stock had earned Neutral rating from Ladenburg Thalmann when it published its report on March 24th, 2017. The stock was given Buy rating by Maxim Group in its report released on December 19th, 2016, the day when the price target on the stock was placed at $7. FBR & Co. was of a view that NYMT is Mkt Perform in its latest report on October 10th, 2016 while giving it a price target of $6.25. Barclays thinks that NYMT is worth Equal Weight rating. This was contained in the firm’s report on March 1st, 2016 in which the stock’s price target was also moved to $5.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 3 believe it has the potential for further growth, thus rating it as Hold while 0 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $5.85. The price of the stock the last time has raised by 7.35% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 35.84.
The shares of the company dipped by 0.00% during the trading session on Wednesday, reaching a low of $5.98 while ending the day at $5.99. During the trading session, a total of 2.67 million shares were traded which represents a -11.89% decline from the average session volume which is 2.39M shares. NYMT had ended its last session trading at 5.99. New York Mortgage Trust, Inc. currently has a market cap of $1.10B, while its P/E ratio stands at 9.46, while its P/E earnings growth sits at 2.11, with a beta of 0.93. New York Mortgage Trust, Inc. debt-to-equity ratio currently stands at 15.13, while its quick ratio hovers at . NYMT 52-week low price stands at $5.58 while its 52-week high price is $6.54.
The New York Mortgage Trust, Inc. generated $21.87 million in revenue during the last quarter, which is slightly higher than the $21.76 million predicted by analysts. New York Mortgage Trust, Inc. has the potential to record 0.63 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Morgan Stanley published a research note on March 13th, 2019 where it informed investors and clients that Elanco Animal Health Incorporated (NYSE:ELAN) is now rated as Equal-Weight. Their price target on the stock stands at $34. Maxim Group also rated ELAN as Reiterated on February 21st, 2018, with its price target of $6.25 suggesting that ELAN could surge by 8.99% from its current share price. Even though the stock has been trading at $31.64/share, analysts expect it to surge higher by -0.19% to reach $34.70/share. It started the day trading at $31.67 and traded between $30.95 and $31.58 throughout the trading session.
The stock has a high of $37.61 for the year while the low is $28.00. The company’s P/E ratio currently sits at 106.69, while the P/B ratio is 0.96. At the moment, only of Elanco Animal Health Incorporated shares were sold short. The company’s average trading volume currently stands at 7.42M shares, which means that the short-interest ratio is just 4.74 days. Over the past seven days, the company moved, with its shift of 6.33%. Looking further, the stock has dropped -5.39% over the past 90 days while it lost over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. Morgan Stanley Investment Managem sold more ELAN shares, decreasing its portfolio by -0.51% during the last quarter. This move now sees Morgan Stanley Investment Managem selling -45,728 shares in the last quarter, thus it now holds 8,873,797 shares of ELAN, with a total valuation of $268,343,621. The Vanguard Group Inc meanwhile bought more ELAN shares in the recently filed quarter, changing its stake to $188,162,443 worth of shares. Amundi Pioneer Asset Management followed the path by increasing its ELAN portfolio by +115,239.56% in the quarter. This means that Amundi Pioneer Asset Management bought 5,761,978 shares in the last quarter and now controls 5,766,978 shares of the ELAN stock, with the valuation hitting $174,393,415.
Similarly, Fidelity Management Research Co increased its Elanco Animal Health Incorporated shares by +33.32% during the recently filed quarter. After buying 1,094,179 shares in the last quarter, the firm now controls 4,377,841 shares of Elanco Animal Health Incorporated which are valued at $132,385,912. In the same vein, Wellington Management Co LLP increased its Elanco Animal Health Incorporated shares by during the most recent reported quarter. The firm bought 1,592,085 shares during the quarter which increased its stakes to 3,940,690 shares and is now valued at $119,166,466. Following these latest developments, around 80.30% of Elanco Animal Health Incorporated stocks are owned by institutional investors and hedge funds.